SAB Biotherapeutics Provides SAB-142 Trial Update
16 avr. 2024 07h15 HE
|
SAB Biotherapeutics, Inc.
SAB Biotherapeutics provides update on SAB-142 clinical trial for type 1 diabetes
SAB Biotherapeutics to Present at INNODIA Annual Meeting
08 avr. 2024 07h15 HE
|
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. today announced their Chief Medical Officer will share an overview of the SAB-142 clinical development plan at INNODIA.
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
04 avr. 2024 07h15 HE
|
SAB Biotherapeutics, Inc.
Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that...
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
29 mars 2024 07h15 HE
|
SAB Biotherapeutics, Inc.
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release...
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
25 mars 2024 10h15 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
23 févr. 2024 08h00 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08 févr. 2024 08h00 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics Announces Executive Leadership Change
02 févr. 2024 07h30 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
23 janv. 2024 17h58 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is...
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
02 janv. 2024 16h30 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human...